Sign in
Knowstox

Fundamentals snapshot

Prenetics Global Limited

PRE · NGM · Consumer Defensive · Packaged Foods

Current price

$16.98

52-week range

$11.37 - $27.24

Market cap

$331.35M

One-glance verdict

Undervalued

$29.80 our estimate vs market $16.98

Wall Street consensus: $38.44 (29.0% higher than our fair-value estimate)

Balance sheet

Healthy

-158.21x Concerning

Net cash $127.88M. Interest coverage shows how many times profit covers the interest bill.

What this company does

Prenetics Global Limited

Prenetics Global Limited sells at-home health tests and personalized genetic reports for individuals hoping to improve their well-being and lifespan. Their main money comes from selling these health products directly to consumers, which is important because it shows people are interested in taking a proactive role in their health.

Price history

How the share price has moved

—
Loading price history…

Is it cheap or expensive?

Fair value $29.80 vs current price $16.98

Wall Street consensus is the average analyst price target: $38.44 (29.0% higher than our fair-value estimate).

Our most-likely fair value is $29.80 a share — about 75.5% above today's price of $16.98, so the stock currently looks cheap (undervalued).

undervalued

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Base

Growth 15.0% · Discount 7.2% · Terminal 3.0%

$29.80

Bear

Growth 5.0% · Discount 7.2% · Terminal 3.0%

$19.79

Bull

Growth 25.0% · Discount 7.2% · Terminal 3.0%

$46.53

Is it drowning in debt?

Healthy

Net cash $127.9M - more cash than debt. Interest coverage -158.2x.

Net debt $-127.88M
Interest coverage -158.21x

Prenetics Global Limited is healthier than 0 of 1 peers on balance-sheet leverage.

Healthy
Worse cushion Baseline Better cushion
PRE BASELINE Prenetics Global Limited

Total debt $682.00K Interest coverage -158.21x This is the baseline the peer rows are being compared against.

-158.21x

What you should know

The case for and against PRE

2 Rewards 1 Risk

Rewards

  • Revenue grew 479.8% last year.
  • Free cash flow was positive in 1/10 years.

Risks

  • Return on equity was -47.0% last year — the company lost money on shareholders' equity.

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
—
Forward P/E
-7.89x
P/B
3.15x
P/S
2.14x
EV/EBITDA
-2.73x
PEG ratio
—

Profitability

How much profit each dollar creates

Gross margin
57.8%
Operating margin
-45.1%
Net margin
-30.4%
ROE
-47.0%
ROA
-18.9%

Health

Liquidity and balance-sheet strength

Debt / equity
0.01x
Current ratio
4.04x
Quick ratio
3.66x
Total debt
$682.00K
Total cash
$128.56M

Growth

How the business has been compounding

Revenue TTM
$154.59M
Revenue 5Y CAGR
91.5%
EPS TTM
-3.10
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$-21.83M
Free CF TTM
$-76.39M
FCF margin
-49.4%

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
—
Last ex-div date
—